RxDoctor Payments Data

Kevin Shinal, MD

Cardiovascular Disease · Paoli, PANPI 1568430197

Payments from drug & device makers

$205,288in general payments, 2019–2025

Across 306 payments — averaging $670.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$173K
  • Lilly USA, LLC$24K
  • Eli Lilly$7K
  • Pfizer$160
  • Novartis$143
  • Amgen$137
  • plus $704 from 15 others

What the payments were for

  • Consulting fees$9,2505%
  • Speaking & faculty fees$186,00391%
  • Travel & lodging$4,2692%
  • Food & beverage$5,7593%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,288 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,123,221
Medicare patients
2,116
Services billed
7,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban581$686,215
XareltoRivaroxaban185$197,732
Repatha SureclickEvolocumab60$54,876
Praluent PenAlirocumab38$30,577
JardianceEmpagliflozin21$29,609
EntrestoSacubitril/Valsartan19$17,474
BrilintaTicagrelor17$13,565
Atorvastatin Calcium755$9,989
Ezetimibe248$8,623
Metoprolol Succinate487$8,226
Rosuvastatin Calcium463$7,906
Flecainide Acetate104$6,072
Losartan Potassium267$3,613
Amlodipine Besylate456$3,052
Diltiazem 24hr Er (Cd)Diltiazem Hcl83$2,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$686,215581 claims
Johnson & JohnsonXarelto$104$197,732185 claims
Boehringer IngelheimJardiance$172,703$29,60921 claims
NovartisEntresto$143$17,47419 claims
AstraZenecaBrilinta$27$13,56517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →